Entero Therapeutics Inc
Company Profile
Business description
Entero Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company’s programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.
Contact
777 Yamato Road
Suite 502
Boca RatonFL33431
USAT: +1 561 589-7020
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
2
Stocks News & Analysis
stocks
Ask the analyst: How reliant are Guzman shares on international growth?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,945.60 | 54.80 | 0.62% |
| CAC 40 | 7,822.00 | 99.91 | 1.29% |
| DAX 40 | 24,370.93 | 361.55 | 1.51% |
| Dow JONES (US) | 44,484.49 | 229.71 | 0.52% |
| FTSE 100 | 8,972.64 | 46.09 | 0.52% |
| HKSE | 24,498.95 | 18.81 | -0.08% |
| NASDAQ | 20,885.65 | 155.16 | 0.75% |
| Nikkei 225 | 39,947.75 | 46.56 | 0.12% |
| NZX 50 Index | 12,896.89 | 8.52 | -0.07% |
| S&P 500 | 6,297.36 | 33.66 | 0.54% |
| S&P/ASX 200 | 8,694.30 | 55.30 | 0.64% |
| SSE Composite Index | 3,516.83 | 13.05 | 0.37% |